Mycobacterium tuberculosis pyrazinamide resistance determinants: A multicenter study

mBio

Volumn 5, Issue 5, 2014, Pages

  Miotto, Paolo ^a   Cabibbe, Andrea M ^a   Feuerriegel, Silke ^b,c   Casali, Nicola ^d,e   Drobniewski, Francis ^d,e   Rodionova, Yulia ^f   Bakonyte, Daiva ^g   Stakenas, Petras ^g   Pimkina, Edita ^g   Augustynowicz Kopeć, Ewa ^h   Degano, Massimo ^a   Ambrosi, Alessandro ⁱ   Hoffner, Sven ^j   Mansjö, Mikael ^j   Werngren, Jim ^j   Rüsch Gerdes, Sabine ^k   Niemann, Stefan ^b,c   Cirillo, Daniela M ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Molecular Mycobacteriology   (Germany)

^c German Center for Infection Research   (Germany)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f Samara TB Service   (Russian Federation)

^g VILNIUS UNIVERSITY   (Lithuania)

^h NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

ⁱ VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^j SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^k RESEARCH CENTER BORSTEL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PYRAZINAMIDE; AMIDASE; PNCA PROTEIN, MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMPUTER MODEL; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HOMOPLASY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PNCA GENE; CLINICAL TRIAL; DNA SEQUENCE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MULTICENTER STUDY; MUTATION; PHYLOGENY; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

AMIDOHYDROLASES; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; GENETIC VARIATION; HUMANS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PHYLOGENY; PYRAZINAMIDE; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS;

EID: 84908425946     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01819-14     Document Type: Article

References (39)

1. Girling DJ. 1984. The role of pyrazinamide in primary chemotherapy for pulmonary tuberculosis. Tubercle 65:1- 4. http://dx.doi.org/10.1016/ 0041-3879(84)90024-2.
2. Mitchison DA. 1985. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66:219 -225. http://dx.doi.org/10.1016/0041 -3879(85)90040-6.
3. Mitchison DA. 2000. Role of individual drugs in the chemotherapy of tuberculosis. Int. J. Tuberc. Lung Dis. 4:796-806.
4. Zhang Y, Yew WW. 2009. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 13:1320-1330.
5. Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, Chang KC, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, Goletti D, Günther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, Rüsch- Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew WW, Zellweger JP, Cirillo DM, TBNET. 2014. Management of patients with multidrugresistant/ extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur. Respir. J. 44:23- 63. http://dx.doi.org/10.1183/ 09031936.00188313.
6. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK. 2012. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380:986 -993. http://dx.doi.org/10.1016/S0140 -6736(12)61080-0.
7. Horne DJ, Pinto LM, Arentz M, Lin SY, Desmond E, Flores LL, Steingart KR, Minion J. 2013. Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for firstline and second-line antituberculosis drugs. J. Clin. Microbiol. 51: 393-401. http://dx.doi.org/10.1128/JCM.02724-12.
8. Hoffner S, Angeby K, Sturegård E, Jönsson B, Johansson A, Sellin M, Werngren J. 2013. Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience. Int. J. Tuberc. Lung Dis. 17:1486-1490. http://dx.doi.org/10.5588/ijtld.13.0195.
9. Piersimoni C, Mustazzolu A, Giannoni F, Bornigia S, Gherardi G, Fattorini L. 2013. Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum. J. Clin. Microbiol. 51:291-294. http://dx.doi.org/10.1128/JCM.01838-12.
10. Zhang Y, Permar S, Sun Z. 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51:42-49.
11. Ling DI, Zwerling AA, Pai M. 2008. Rapid diagnosis of drug-resistant TB using line probe assays: from evidence to policy. Expert Rev. Respir. Med 2:583-588. http://dx.doi.org/10.1586/17476348.2.5.583.
12. Singh P, Mishra AK, Malonia SK, Chauhan DS, Sharma VD, Venkatesan K, Katoch VM. 2006. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in mycobacteria. J. Commun. Dis. 38:288-298.
13. Köser CU, Comas I, Feuerriegel S, Niemann S, Gagneux S, Peacock SJ. 2014. Genetic diversity within Mycobacterium tuberculosis complex impacts on the accuracy of genotypic pyrazinamide drug-susceptibility assay. Tuberculosis (Edinb.) 94:451- 453. http://dx.doi.org/10.1016/ j.tube.2014.04.002.
14. Feuerriegel S, Köser CU, Niemann S. 2014. Phylogenetic polymorphisms in antibiotic resistance genes of the Mycobacterium tuberculosis complex. J. Antimicrob. Chemother. 69:1205-1210. http://dx.doi.org/10.1093/jac/ dkt535.
15. Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, Corander J, Bryant J, Parkhill J, Nejentsev S, Horstmann RD, Brown T, Drobniewski F. 2014. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat. Genet. 46: 279-286. http://dx.doi.org/10.1038/ng.2878.
16. Comas I, Coscolla M, Luo T, Borrell S, Holt KE, Kato-Maeda M, Parkhill J, Malla B, Berg S, Thwaites G, Yeboah-Manu D, Bothamley G, Mei J, Wei L, Bentley S, Harris SR, Niemann S, Diel R, Aseffa A, Gao Q, Young D, Gagneux S. 2013. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat. Genet. 45:1176-1182. http://dx.doi.org/10.1038/ng.2744.
17. Chang KC, Leung CC, Yew WW, Leung EC, Leung WM, Tam CM, Zhang Y. 2012. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis. Antimicrob. Agents Chemother. 56:5465-5475. http://dx.doi.org/10.1128/AAC.01300-12.
18. Zumla AI, Gillespie SH, Hoelscher M, Philips PP, Cole ST, Abubakar I, McHugh TD, Schito M, Maeurer M, Nunn AJ. 2014. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect. Dis. 14:327-340. http://dx.doi.org/10.1016/ S1473-3099(13)70328-1.
19. Nebenzahl-Guimaraes H, Jacobson KR, Farhat MR, Murray MB. 2014. Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 69:331-342. http://dx.doi.org/10.1093/jac/ dkt358.
20. Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, III, Wang H, Zhang W, Zhang Y. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333:1630 -1632. http://dx.doi.org/10.1126/ science.1208813.
21. Zhang S, Chen J, Shi W, Liu W, Zhang W, Zhang Y. 2013. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerging Microbes Infect. 2:e34. http://dx.doi.org/10.1038/emi.2013.38.
22. Alexander DC, Ma JH, Guthrie JL, Blair J, Chedore P, Jamieson FB. 2012. Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA. J. Clin. Microbiol. 50:3726-3728. http://dx.doi.org/10.1128/JCM.00620-12.
23. Tan Y, Hu Z, Zhang T, Cai X, Kuang H, Liu Y, Chen J, Yang F, Zhang K, Tan S, Zhao Y. 2014. Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates from southern China. J. Clin. Microbiol. 52:291-297. http:// dx.doi.org/10.1128/JCM.01903-13.
24. Köser CU, Ellington MJ, Cartwright EJ, Gillespie SH, Brown NM, Farrington M, Holden MT, Dougan G, Bentley SD, Parkhill J, Peacock SJ. 2012. Routine use of microbial whole genome sequencing in diagnostic and public health microbiology. PLoS Pathog. 8:e1002824. http:// dx.doi.org/10.1371/journal.ppat.1002824.
25. Barnes PF, Cave MD. 2003. Molecular epidemiology of tuberculosis. N. Engl. J. Med. 349:1149-1156. http://dx.doi.org/10.1056/NEJMra021964.
26. Allix-Béguec C, Harmsen D, Weniger T, Supply P, Niemann S. 2008. Evaluation and strategy for use of MIRU-VNTRplus, a multifunctional database for online analysis of genotyping data and phylogenetic identification of Mycobacterium tuberculosis complex isolates. J. Clin. Microbiol. 46:2692-2699. http://dx.doi.org/10.1128/JCM.00540-08.
27. Weniger T, Krawczyk J, Supply P, Niemann S, Harmsen D. 2010. MIRU-VNTRplus: a web tool for polyphasic genotyping of Mycobacterium tuberculosis complex bacteria. Nucleic Acids Res. 38:W326-W331. http://dx.doi.org/10.1093/nar/gkq351.
28. Miotto P, Piana F, Penati V, Canducci F, Migliori GB, Cirillo DM. 2006. Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy. J. Clin. Microbiol. 44:2485-2491. http://dx.doi.org/10.1128/ JCM.00083-06.
29. Juréen P, Werngren J, Toro JC, Hoffner S. 2008. Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 52:1852-1854. http://dx.doi.org/10.1128/ AAC.00110-08.
30. Singh P, Wesley C, Jadaun GP, Malonia SK, Das R, Upadhyay P, Faujdar J, Sharma P, Gupta P, Mishra AK, Singh K, Chauhan DS, Sharma VD, Gupta UD, Venkatesan K, Katoch VM. 2007. Comparative evaluation of Löwenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 45:76-80. http://dx.doi.org/10.1128/JCM.00951-06.
31. Mirabal NC, Yzquierdo SL, Lemus D, Madruga M, Milián Y, Echemendía M, Takiff H, Martin A, Van der Stuyf P, Palomino JC, Montoro E. 2010. Evaluation of colorimetric methods using nicotinamide for rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 48:2729 -2733. http://dx.doi.org/10.1128/JCM.00311 -10.
32. Petrella S, Gelus-Ziental N, Maudry A, Laurans C, Boudjelloul R, Sougakoff W. 2011. Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide. PLoS One 6:e15785. http://dx.doi.org/10.1371/ journal.pone.0015785.
33. Guerois R, Nielsen JE, Serrano L. 2002. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J. Mol. Biol. 320:369 -387. http://dx.doi.org/10.1016/S0022 -2836(02)00442-4.
34. Benjamini Y, Yekutieli D. 2001. The control of the false discovery rate in multiple testing under dependency. Ann. Stat. 24:1165-1188. http:// dx.doi.org/10.1214/aos/1013699998.
35. Morgan JN, Sonquist JA. 1963. Problems in the analysis of survey data, and a proposal. J. Am. Stat. Assoc. 58:415-434. http://dx.doi.org/10.1080/ 01621459.1963.10500855.
36. Breiman L, Friedman JH, Olshen RA, Stone CJ. 1984. Classification and regression trees, 1st ed. Chapman and Hall/CRC, New York, NY.
37. Mingers J. 1987. Expert systems rule induction with statistical data. J. Oper. Res. Soc. 38:39-47. http://dx.doi.org/10.2307/2582520.
38. Hothorn T, Hornik K, Zeileis A. 2006. Unbiased recursive partitioning: a conditional inference framework. J. Comput. Graph. Stat. 15:651-674. http://dx.doi.org/10.1198/106186006X133933.
39. Strasser H, Weber C. 1999. On asymptotic theory permutation statistics. Math. Methods Stat. 8:220-250.